Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control - Wikidata - awgldk - TriplyDB

Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control

Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control

http://www.wikidata.org/entity/Q27657777

about

In-gel activity-based protein profiling of a clickable covalent ERK1/2 inhibitor Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.CSAR benchmark exercise 2011-2012: evaluation of results from docking and relative ranking of blinded congeneric series Docking challenge: protein sampling and molecular docking performance.Transcription factor Etv5 is essential for the maintenance of alveolar type II cells.Rational design of non-resistant targeted cancer therapies Small-molecule inhibitors of the ERK signaling pathway: Towards novel anticancer therapeutics.Chiral kinase inhibitors.Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition Structure-based virtual screening of glycogen synthase kinase 3β inhibitors: analysis of scoring functions applied to large true actives and decoy sets.A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.The cellular thermal shift assay for evaluating drug target interactions in cells.Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells.Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer.Regulation of cell proliferation by ERK and signal-dependent nuclear translocation of ERK is dependent on Tm5NM1-containing actin filaments.Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma.Slow inhibition and conformation selective properties of extracellular signal-regulated kinase 1 and 2 inhibitors Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.Targeting RAS-mutant cancers: is ERK the key?Phosphoproteome analysis of the MAPK pathway reveals previously undetected feedback mechanisms.The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling.Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics.Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.Computation of relative binding free energy for an inhibitor and its analogs binding with Erk kinase using thermodynamic integration MD simulation.Prediction of amino acid positions specific for functional groups in a protein family based on local sequence similarity.Structure, signaling and the drug discovery of the Ras oncogene protein.Structure-Guided Strategy for the Development of Potent Bivalent ERK Inhibitors.Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.A high throughput assay to identify substrate-selective inhibitors of the ERK protein kinases.Differential sensing of MAP kinases using SOX-peptides.

P2860

Q27716899-4364606D-FDEC-49F3-A074-BCF5E6A45EA0 Q27851896-DC2C2D49-7792-4E7F-8CDF-F2C0BEE95EE2 Q27852017-7E4CBBD4-DC1C-46D6-ADEC-EB41EDD865EC Q30543685-B0B641A0-B39D-4493-A302-DF79AB9E91F4 Q30607323-E5E07336-D97A-4C66-A206-4D60594AC643 Q33569337-631C709B-EDC8-4266-BCE3-F8F30E32E757 Q33594692-9A543835-9EAB-4F13-B530-D059BB69986B Q33756524-A240E13E-B0B0-468C-89FD-FEC88322AB78 Q33811207-C5D6510D-7377-4C44-9DC7-FA6A9634F8D7 Q33880093-5D58A419-4E22-4205-A471-C3B3086CFCD6 Q33934472-0342DF47-BAF2-496C-8399-0CA7759B2173 Q34132936-458A66B5-9BAD-40DE-813F-F3A279D13497 Q34307356-42A59547-2D27-47B1-83AB-638B6C690BBD Q34432745-95730497-CD24-45E2-AFEE-7F5C383C463A Q35552019-B0CA1570-ED69-4D75-863A-DC644C273FA0 Q35740070-741160F7-94CD-430F-A9F9-2E166730B583 Q36063672-2421AB53-B1B1-4E6B-9F68-0A83ADCCEBB4 Q36128825-8ACA5190-F381-4178-A1B0-216539AF626E Q36359700-8E089692-62B9-4153-BF2B-2C5867EF77DD Q36401173-2DB64E45-4B6D-4AB7-BFA0-08F474170EB2 Q36493862-3DA281FC-1F40-4C8B-A5D6-2BE9175DCE42 Q36759354-BDDAC1B1-D3AD-4453-B2F6-6837253ED428 Q38267209-E79DEEBF-41D2-4B24-BE29-4F373C6BC976 Q38391612-BFED9735-4258-4FF5-B3FC-DBE86AB8ACFC Q38397326-24D10835-1999-478F-8D97-FE1FADC0ADD4 Q38808985-EB7C9417-8B81-4392-811D-02DE7F147245 Q38895275-CD6F2978-597A-4104-B34B-0F734BEBC4D4 Q38904777-88D718E6-CDA7-419B-A055-55DF5F1C63E6 Q38947384-E7EC249D-E6D0-4156-A5EF-3EC8E14A3BFB Q38959137-7797E9CE-9991-4110-8EDA-73C22FCDD03A Q38965270-A79EDB6E-2061-4DBB-99F6-369360EB28CE Q39029234-7A1A0F6F-7136-4AF6-92FE-C38A7DF5CFBF Q39067618-455AF95D-4111-4F6D-B044-33AF7E945B8B Q39551290-69604995-46E2-43A3-B86C-533F2F243C96 Q40342782-141D09F0-DE4E-4EF8-8CFC-DEDB5FF049DE Q42353910-6D2DC2E6-236C-4AF6-A480-7FD3F9FDA853 Q46178714-4D51BCE3-CAEC-4105-B07C-D4F0FC475C1F Q47611731-B9B70EA0-E9CE-43E8-95AA-30AD31A35F91 Q50925733-747FDC99-556D-4D4A-AA44-AE29E19A0CAA Q54315224-C6A42742-098F-46F9-B983-4BF59EE0F4D2

P2860

Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control

http://www.wikidata.org/entity/Q27657777

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Structure-guided design of pot ...... ) using conformational control

@ast

Structure-guided design of pot ...... ) using conformational control

@en

Structure-guided design of pot ...... ) using conformational control

@nl

type

label

Structure-guided design of pot ...... ) using conformational control

@ast

Structure-guided design of pot ...... ) using conformational control

@en

Structure-guided design of pot ...... ) using conformational control

@nl

prefLabel

Structure-guided design of pot ...... ) using conformational control

@ast

Structure-guided design of pot ...... ) using conformational control

@en

Structure-guided design of pot ...... ) using conformational control

@nl

P1433

Q27657777-D082A31E-1C59-4875-8938-B362E8B54223

P1476

Q27657777-1D7DF046-DFDD-4C37-AF70-B40B9637E533

P2093

Q27657777-01CC2B19-9F08-49FC-8482-7CC71D394073

Q27657777-0B1D2513-467A-49D0-A24A-B8B2DF1AE8B2

Q27657777-15AD83EA-8F24-4332-9ED8-A3B5F42EF1AF

Q27657777-22ECEACC-7433-4600-958F-292CD613E535

Q27657777-4A225309-D2AE-403A-A856-720594C285FE

Q27657777-4B0E3830-E26D-4C35-AC4C-668F94015083

Q27657777-5618BA5C-FDFC-4909-B012-73C8D2B04746

Q27657777-63DAF741-55C7-4B5A-B1A6-B28B80F8E6D7

Q27657777-741D22B8-8180-4425-A876-99D60B98A389

Q27657777-764AA24E-FAB1-4C52-8B3D-E747596E1FFB

P304

Q27657777-F8749EA1-51EF-4352-A439-9B95C189C42F

P31

Q27657777-5F638BEA-2A72-40DF-AC18-69207E9EE344

P356

Q27657777-5B4BC2F8-267D-4181-9832-62A66FF12256

P407

Q27657777-8F2AC4C8-4E31-4920-AE65-C7DF3FBBB784

P433

Q27657777-B06306AE-824A-4A68-A15E-4CD63AFC9BA3

P478

Q27657777-C8DF5AB5-CD67-4841-A46C-3FA6DDA7E722

P577

Q27657777-D1BAE1F3-4575-41D2-9199-A01AA408CFA9

P5875

Q27657777-BC57CC24-8369-4C3C-A472-3D5B303F99B1

P698

Q27657777-D2E4A4F5-2DC3-461F-9527-8D35D8CF4125

P356

P1433

Journal of Medicinal Chemistry

P1476

Structure-guided design of pot ...... ) using conformational control

@en

P2093

Alex M Aronov

http://www.w3.org/2001/XMLSchema#string

Ernst ter Haar

http://www.w3.org/2001/XMLSchema#string

Francois Maltais

http://www.w3.org/2001/XMLSchema#string

Gabriel Martinez-Botella

http://www.w3.org/2001/XMLSchema#string

Guanjing Chen

http://www.w3.org/2001/XMLSchema#string

Guy W Bemis

http://www.w3.org/2001/XMLSchema#string

James W Janetka

http://www.w3.org/2001/XMLSchema#string

Jeremy Green

http://www.w3.org/2001/XMLSchema#string

Jingrong Cao

http://www.w3.org/2001/XMLSchema#string

Judy Straub

http://www.w3.org/2001/XMLSchema#string

P304

6362-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM900630Q

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38010324

http://www.w3.org/2001/XMLSchema#string

P698

19827834

http://www.w3.org/2001/XMLSchema#string